CIK 0001799788 · Non-accelerated filer<br>Smaller reporting company
Greenwich LifeSciences, Inc.
Sign in to watch- Ticker
- GLSI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 205473709
- Phone
- 203-434-3290
- Business address
- 3992 BLUEBONNET DR, BUILDING 14, STAFFORD, TX, 77477
- 4 Open-market buy CEO and CFO bought 2,000 shares at $13.81 ($27,620)
- 4 Open-market buy CEO and CFO bought 5,500 shares at $13.18 ($72,490)
- 4 Open-market buy VP Clinical Reg Affairs bought 1,000 shares at $15.15 ($15,150)
- 4 Open-market buy CEO and CFO bought 1,500 shares at $15.89 ($23,835)
- 4 Open-market buy VP Clinical Reg Affairs bought 1,000 shares at $16.00 ($16,000)
- D Other Notice of Sales of Unregistered Securities
- 8-K Event Material agreement · Unregistered share sale
- 4 Open-market buy CEO and CFO bought 174,825 shares at $14.30 ($2,499,998)
- 10-Q Report Quarterly Report
- NT 10-Q Other NT 10-Q
- 10-K Report Annual Report
- 4 Open-market buy CEO and CFO bought 3,000 shares at $19.08 ($57,240)
- NT 10-K Other NT 10-K
- 4 Open-market buy CEO and CFO bought 2,500 shares at $19.98 ($49,950)
- 4 Open-market buy CEO and CFO bought 1,500 shares at $17.68 ($26,520)
- 4/A Open-market buy CEO and CFO bought 3,500 shares at $12.49 ($43,715)
- 4 Open-market buy CEO and CFO bought 30,500 shares at $12.49 ($380,945)
- 4 Open-market buy CEO and CFO bought 4,100 shares at $13.03 ($53,423)
- 4 Open-market buy CEO and CFO bought 10,800 shares at $11.16 ($120,528)
- 8-K Event Auditor change
Page 4 of 14 · 279 filings